ARMATA PHARMACEUTICALS INC (ARMP) Stock Price, Quote, News and Overview
NYSEARCA:ARMP - NYSE Arca - US04216R1023 - Common Stock - Currency: USD
ARMP Quote, Performance and Key Statistics
NYSEARCA:ARMP (2/21/2025, 8:04:00 PM)
2.105
+0.1 (+4.73%)
The current stock price of ARMP is 2.105 USD. In the past month the price decreased by -3.44%. In the past year, price decreased by -29.83%.
ARMP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ARMP
Company Profile
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 66 full-time employees. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The firm's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Company Info
ARMATA PHARMACEUTICALS INC
5005 Mcconnell Ave
Los Angeles CALIFORNIA 90292 US
CEO: Todd R. Patrick
Employees: 66
Company Website: https://www.armatapharma.com/
Investor Relations: https://investor.armatapharma.com/investors-overview
Phone: 13106652928
ARMATA PHARMACEUTICALS INC / ARMP FAQ
What is the stock price of ARMATA PHARMACEUTICALS INC today?
The current stock price of ARMP is 2.105 USD. The price increased by 4.73% in the last trading session.
What is the ticker symbol for ARMATA PHARMACEUTICALS INC stock?
The exchange symbol of ARMATA PHARMACEUTICALS INC is ARMP and it is listed on the NYSE Arca exchange.
On which exchange is ARMP stock listed?
ARMP stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for ARMATA PHARMACEUTICALS INC stock?
7 analysts have analysed ARMP and the average price target is 7.14 USD. This implies a price increase of 239.19% is expected in the next year compared to the current price of 2.105. Check the ARMATA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARMATA PHARMACEUTICALS INC worth?
ARMATA PHARMACEUTICALS INC (ARMP) has a market capitalization of 76.16M USD. This makes ARMP a Micro Cap stock.
How many employees does ARMATA PHARMACEUTICALS INC have?
ARMATA PHARMACEUTICALS INC (ARMP) currently has 66 employees.
What are the support and resistance levels for ARMATA PHARMACEUTICALS INC (ARMP) stock?
ARMATA PHARMACEUTICALS INC (ARMP) has a support level at 2.04 and a resistance level at 2.17. Check the full technical report for a detailed analysis of ARMP support and resistance levels.
Is ARMATA PHARMACEUTICALS INC (ARMP) expected to grow?
The Revenue of ARMATA PHARMACEUTICALS INC (ARMP) is expected to grow by 42.1% in the next year. Check the estimates tab for more information on the ARMP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARMATA PHARMACEUTICALS INC (ARMP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARMP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARMP, evaluating the profitability, health, valuation and growth aspects
- ARMATA PHARMACEUTICALS INC (ARMP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARMATA PHARMACEUTICALS INC (ARMP) Sales and EPS estimates to see what analysts future expectations are.
- ARMATA PHARMACEUTICALS INC (ARMP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARMATA PHARMACEUTICALS INC (ARMP) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARMATA PHARMACEUTICALS INC (ARMP) Stock Chart to make your own analysis
- ARMATA PHARMACEUTICALS INC (ARMP) Latest news and press-releases to stay up to date.
Does ARMATA PHARMACEUTICALS INC (ARMP) stock pay dividends?
ARMP does not pay a dividend.
When does ARMATA PHARMACEUTICALS INC (ARMP) report earnings?
ARMATA PHARMACEUTICALS INC (ARMP) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of ARMATA PHARMACEUTICALS INC (ARMP)?
ARMATA PHARMACEUTICALS INC (ARMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).
What is the Short Interest ratio of ARMATA PHARMACEUTICALS INC (ARMP) stock?
The outstanding short interest for ARMATA PHARMACEUTICALS INC (ARMP) is 0.17% of its float. Check the ownership tab for more information on the ARMP short interest.
ARMP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ARMP. When comparing the yearly performance of all stocks, ARMP is a bad performer in the overall market: 84.02% of all stocks are doing better.
ARMP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARMP. ARMP has a bad profitability rating. Also its financial health evaluation is rather negative.
ARMP Financial Highlights
Over the last trailing twelve months ARMP reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 25.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ARMP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ARMP. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 46.17% and a revenue growth 42.1% for ARMP